share_log

Goldman Sachs Maintains Buy on Dynavax Technologies, Lowers Price Target to $21

Benzinga Real-time News ·  Nov 4, 2022 10:31

Goldman Sachs analyst Madhu Kumar maintains Dynavax Technologies (NASDAQ:DVAX) with a Buy and lowers the price target from $24 to $21.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment